An analysis of the NRG Oncology clinical trial NRG-RTOG 9202 showed that the interval of time to biochemical failure (IBF), or the time it takes for previously treated cancer to return as indicated by prostate-specific antigen (PSA) rise, could be used as a surrogate endpoint for locally advanced prostate cancer.
FGD4 (Frabin) is an F-actin binding protein with GTP / GDP exchange activity specific for CDC42 . It is involved in the reorganization of the cytoskeleton act, which requires both actin binding and CDC42 activating function of FGD4. Expression of FGD4 is altered in patients with different hereditary motor and sensory neuropathies as a result of demyelination of neurons.
Cancer cell metastasis has been recognized as one hallmark of malignant tumor progression; thus, measuring the motility of cells, especially tumor cell migration, is important for evaluating the therapeutic effects of anti-tumor drugs.
An international team of cancer researchers from Denmark and Germany has used cancer patient data to develop a computer model that can predict the progression of prostate cancer. The model is currently being implemented at a prostate cancer clinic in Germany. The researchers have also found an enzyme that appears to trigger some of the first mutations in prostate cancer.
How does a normal cell turn into deadly cancer? Seeking an answer to this question, and working alongside other international working groups, researchers from Charité Universitätsmedizin Berlin examined the tumor genomes of nearly 300 prostate cancer patients.
The Next-Generation Copy Number Alteration (NG-CNA) assay can analyze small amounts of material to estimate metastatic risk, reports The Journal of Molecular Diagnostics
For men newly diagnosed with prostate cancer or patients previously treated, the risk of metastasis is a crucial determinant of whether to choose conservative management or undergo further treatment.
A team of researchers developed a novel model of partial bladder outlet obstruction (pBOO) in female swine and used this model to show that even after inducing severe urinary outlet resistance and damage to the bladder.
We know that the bladder is a poorly understood organ, critical for storing metabolic waste. What we do not know is how this unique environment impacts bladder immunity to common diseases such as urinary tract infections (UTI) and bladder cancer
Men with inflammatory bowel disease have four to five times higher risk of being diagnosed with prostate cancer, reports a 20-year study from Northwestern Medicine. This is the first report to show men with inflammatory bowel disease have higher than average PSA (prostate-specific antigen) values, and this group also has a significantly higher risk of potentially dangerous prostate cancer
To investigate whether the maximum Watts factor (WF) is 1 parameter of describing detrusor contraction in male patients with lower urinary tract symptoms (LUTS). Researchers retrospectively reviewed urodynamic data of male subjects with LUTS.
Prostate Cancer researchers from the Bellvitge Biomedical Research Institute (IDIBELL), led by Dr. Álvaro Aytés report a new combined therapy to fight the most aggressive and resistant prostate cancers. The team, which has just published its results in Nature Communications, also includes researchers from the Catalan Institute of Oncology, Columbia University in New York and the University of Bern in Switzerland
A team of engineers and medical researchers found that the technology-enabled surgeons to pick up clinically relevant cancers that were missed when using current visual detection methods. The best approach would be to use both techniques in tandem, according to the findings published today in European Urology